Dr. Agarwal’s Healthcare Restricted is a number one participant in India’s eye care trade, set to debut within the inventory market with its extremely anticipated Preliminary Public Providing (IPO). With sturdy fundamentals and a well-established model, the corporate is producing buzz among the many IPO traders. Let’s get into the small print of the Dr. Agarwal’s Healthcare IPO, exploring its aggressive strengths, financials, GMP (gray market worth), causes to speculate, threat components and get full evaluation and evaluation.
About Dr. Agarwal’s Healthcare Restricted
Based in 2010, Dr. Agarwal’s Healthcare is a trusted title in complete eye care. The corporate offers a spread of companies, together with cataract surgical procedures, LASIK procedures, glaucoma therapies, retinal surgical procedures, and corneal transplants. With over 193 amenities throughout India and 28 hubs below a scalable hub-and-spoke mannequin, the corporate is the most important non-public eye care supplier in India.
Within the six months resulting in September 30, 2024, the corporate served over 1.15 million sufferers and performed 140,787 surgical procedures, underscoring its medical experience and operational scale.
Dr. Agarwal’s Healthcare IPO Subject Particulars
- IPO Date: January 29, 2025 – January 31, 2025
- Worth Band: ₹382 – ₹402 per share
- Lot Dimension: 35 shares
- Subject Dimension: ₹3,027.26 crore
- Contemporary Subject: ₹300 crore
- Supply for Sale (OFS): ₹2,727.26 crore
- Itemizing: BSE and NSE
- Promoters’ Holding (Submit-IPO): Lowered to 37.72%.
IPO Timeline:
- Foundation of Allotment: February 3, 2025
- Refunds Initiation: February 4, 2025
- Itemizing Date: February 5, 2025
The proceeds from the contemporary subject will primarily fund debt compensation and acquisitions, strengthening the corporate’s monetary place.
Aggressive Strengths
- Largest Eye Care Community: Dr. Agarwal’s Healthcare boasts the most important non-public eye care community in India, with amenities in each metropolitan and non-metropolitan areas.
- Complete Companies: The corporate gives end-to-end options for eye care, together with consultations, surgical procedures, optical merchandise, and prescribed drugs.
- Asset-Gentle Hub-and-Spoke Mannequin: Its environment friendly working mannequin permits the corporate to scale operations whereas sustaining excessive profitability.
- Robust Model Fairness: With many years of medical excellence and surgical innovation, Dr. Agarwal’s is a family title in eye care.
- Management by Physician-Promoters: The corporate is led by skilled ophthalmologists, guaranteeing medical experience is central to decision-making.
Monetary Efficiency
| Interval Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Property | 3,393.41 | 2,752.82 | 1,825.17 | 1,026.13 | ||||||||||||||||||||||||||||||||||||
| Income | 837.94 | 1,376.45 | 1,031.49 | 713.78 | ||||||||||||||||||||||||||||||||||||
| Revenue After Tax | 39.56 | 95.05 | 103.23 | 43.16 | ||||||||||||||||||||||||||||||||||||
| Internet Price | 1,502.67 | 1,337.68 | 627.83 | 212.34 | ||||||||||||||||||||||||||||||||||||
| Reserves and Surplus | 1,509.11 | 1,365.86 | 652.63 | 236.27 | ||||||||||||||||||||||||||||||||||||
| Whole Borrowing | 373.68 | 387.79 | 356.18 | 290.18 | ||||||||||||||||||||||||||||||||||||
| Quantity in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||
Sep-2024 column is for six months ending Sep-2024
The corporate has demonstrated constant development in income and profitability, though a dip in ROE highlights the necessity for environment friendly capital utilization post-IPO.
P/E Ratio In comparison with Friends
Dr. Agarwal’s Healthcare IPO Worth Band is Rs 382 to Rs 402 and that is at a P/E ratio of 130.4x. Its friends like Aster DM Healthcare is buying and selling at P/E 136x (Highest) and Narayana Well being at P/E 33x (Lowest) and trade common is 82x. Therefore the IPO worth is overestimated.
Causes to Put money into Dr. Agarwal’s Healthcare IPO
- Management in a Area of interest Market: With a deal with eye care, the corporate dominates a section poised for development in India.
- Scalability: Its asset-light mannequin and acquisition-driven development technique allow fast enlargement.
- Robust Financials: Constant income development and profitability underscore a strong enterprise mannequin.
- Skilled Administration: Led by seasoned medical professionals, the corporate has a confirmed observe report.
Danger Components
- Excessive Valuation: The premium P/E ratio in comparison with friends could restrict upside potential within the quick time period.
- Regulatory Dangers: Adjustments in healthcare laws might influence operations.
- Competitors: Rising competitors within the healthcare sector could have an effect on market share.
- Debt Ranges: The IPO incorporates OFS (which fits to promoting share holders solely) and Contemporary subject. Whereas a portion of IPO proceeds shall be used for debt compensation, current liabilities stay substantial.
Dr. Agarwal’s Healthcare IPO GMP (Gray Market Worth)
As of January 24, 2025, the Dr. Agarwal’s Healthcare IPO instructions a gray market premium (GMP) of ₹80 per share, indicating sturdy demand amongst retail and HNI traders.
Learn how to Apply for Dr. Agarwal’s Healthcare IPO
Buyers can apply through ASBA (Utility Supported by Blocked Quantity) by their financial institution or brokers. UPI-enabled functions can be found for retail traders.
Steps to Apply:
- Log in to your buying and selling account or financial institution’s IPO part.
- Choose “Dr. Agarwal’s Healthcare IPO.”
- Enter bid particulars and make sure the appliance utilizing UPI/ASBA.
Dr. Agarwal’s Healthcare IPO Overview – Ought to You Make investments?
Dr. Agarwal’s Healthcare IPO gives a superb alternative to put money into India’s largest eye care supplier with important development potential.
Nonetheless on the unfavourable facet, the IPO worth is overpriced past the regulatory dangers, excessive competitors and so forth.
Is it Good or Unhealthy for Funding – Must you purchase or not – Make investments with a long-term perspective. Retail traders in search of fast returns on IPO itemizing date ought to keep away from such IPOs because of the excessive valuation.
Disclaimer: This evaluation is for informational functions solely. Seek the advice of your monetary advisor earlier than making funding choices.
